Wockhardt Ltd (WOCKPHARMA)
₹1,849.20
Mkt cap
₹30,048 Cr
P/E ratio
106.00
P/B
6.08
Div yield
0.00%
ROE
6.11%
ROCE
7.55%
EPS (TTM)
₹17.45
Book value
₹304
52W range
1,100–2,153
Sector
Healthcare
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−14.11% from high₹1,849
₹1,100+68.06% from low₹2,153
Current
₹1,849.20
Prev close
₹1,844.00
Day
+0.28%
Price performance
1D
+0.28%
1W
−3.86%
1M
−5.90%
3M
+31.60%
6M
+34.39%
1Y
+1.59%
YTD
+31.50%
Financials
FRevenue, profit & margin
P/E ratio
106.0×
WOCKPHARMA is 211% above the sector median of 34.0×
WOCKPHARMA106.0×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 678 | 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 | |
| Expenses | 675 | 628 | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 | |
| Operating Profit | 3 | 16 | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 | |
| OPM % | 0% | 2% | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% | 23% | 20% | 23% | |
| Other Income | -64 | -0 | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 | 21 | 15 | 67 | |
| Interest | 76 | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 | |
| Depreciation | 56 | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 | |
| Profit before tax | -193 | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 | 67 | 189 | |
| Tax % | 23% | 15% | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% | 10% | 9% | 13% | |
| Net Profit | -237 | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 | 82 | 61 | 164 | |
| EPS in Rs | -14.44 | -9.30 | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 | 4.80 | 3.63 | 10.22 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.60% · closed higher next day 24 of last 58
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Aug '23◦ | 14 Nov '23◦ | 14 Feb '24◦ | 28 May '24◦ | 9 Aug '24◦ | 13 Nov '24◦ | 7 Feb '25 | 29 May '25◦ | 8 Aug '25 | 3 Nov '25 | 10 Feb '26 | 4 May '26◦ |
| Earnings day | −0.04% | −1.47% | −0.96% | +0.56% | +3.03% | −1.62% | −3.13% | +8.80% | −3.25% | +10.32% | +1.27% | +7.86% |
| +1 day | −0.91% | +12.51% | +8.62% | −4.46% | −2.10% | −4.48% | −7.98% | +8.85% | −3.86% | +6.54% | −0.64% | +20.48% |
| +5 days | −4.59% | +16.54% | +26.44% | −7.06% | +2.81% | +8.88% | −16.11% | +11.78% | −0.94% | +3.93% | −1.06% | +10.20% |
| +15 days | +2.10% | +19.96% | +23.53% | +2.34% | +10.24% | +17.35% | −27.32% | +28.51% | −7.01% | −0.88% | −8.57% | +19.31% |
| +30 days | −5.00% | +48.89% | +33.41% | +58.37% | +4.76% | +19.12% | −13.60% | +30.46% | −2.94% | +5.91% | −15.16% | +41.95% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202649.09%Promoter
Promoters49.09%
FIIs7.23%0.14
DIIs9.24%1.72
Public34.44%1.60
Government0.02%0.02
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Wockhardt | ₹1,849.20 | 105.78 | 30,048 | 0.00% | 164 | +687.64% | 965 | +29.88% | 7.55% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts11
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Jul - The copies of Newspaper Advertisement published today i.e. 18th July, 2026 in respect to the information regarding the 27th Annual General Meeting (''AGM'') of the …Business Responsibility and Sustainability Reporting (BRSR) 17 Jul - Wockhardt submitted FY26 BRSR report; disclosed ₹28.08 lakh GST demand under appeal.Reg. 34 (1) Annual Report. 17 JulNotice Of 27Th Annual General Meeting And The Annual Report Of The Company For The Financial Year 2025-26. 17 JulCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.